ArticleVirology journal2025
Analysis of the clinical efficacy of CCBs in patients with severe fever with thrombocytopenia syndrome combined with hypertension.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Explainable Machine Learning Model for Early Prediction of Incident Myocardial Injury in Patients With Severe Fever With Thrombocytopenia Syndrome.Journal of medical virology · 2026Article
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCalcium channel blockers (CCBs), commonly used in the treatment of various cardiovascular diseases, have shown promising potential in inhibiting the formation of viral inclusion bodies by lowering the level of intracellular Ca2+, thereby reducing viral replication. We conducted a retrospective single-center cohort study of SFTS patients with hypertension to assess the impact of CCB therapy on SFTS.
methodsSFTS patients with hypertension treated in Qishan Hospital of Yantai from May 1, 2018, to December 31, 2022, were included. According to the admission criteria, 94 patients with SFTS were divided into the CCBs group (N = 30) and the control group (patients who took other antihypertensive drugs) (N = 64). We observed the severity of the disease, fatality rate, nucleic acid conversion time, nucleic acid's positive rate, and the clinical improvement of the two groups. The effects of different CCBs on nucleic acid conversion were evaluated.
resultsThere was a significant difference in the severity rate between the CCBs and control groups (63.3% vs. 82.8%, P = 0.038). The time of nucleic acid conversion in the CCBs group was significantly shorter than in the control group (P = 0.001). The nucleic acid negative conversion curve differed between the two groups (Log Rank P = 0.010), and the CCBs group was better. The frequency of vomiting and nervous system symptoms in the CCBs group was significantly lower than in the control group (P = 0.049,0.038), and the platelet level was significantly higher in the former than in the latter (P = 0.015). The conversion rate of nucleic acid in patients taking nifedipine was significantly higher than that in patients taking other CCBs (p = 0.036).
conclusionsOur research indicates that CCBs may aid in decreasing disease severity, easing clinical symptoms, and potentially slowing the advancement to severe illness in patients with SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.